window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 6, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

SCLC

  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    First patients dosed in Phase 1 trial of DLL3-targeted radiopharmaceutical for small cell lung cancer

    The first patients have been dosed with MP0712, a DLL3-targeted [...]

    July 3, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Remepy study links Hybridopa brain changes to improved Parkinson’s outcomes
    Categories: Clinical & Regulatory, Digital & Data, Pharmaceuticals and therapeutics, Research & Development
  • Basecamp integrates AI antibiotic and vaccine design models into Claude Science
    Categories: Digital & Data, Drug Discovery & Development, Research & Development
  • AMR Action Fund leads €18M Series A for Telum Therapeutics
    Categories: Biotech & Pharma Business, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top